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the median of the disease range is outside the percentile limits 
of the normal population.6 A simultaneous assessment of mul-
tiple analytes is performed according to the degree of penetra-
tion within the respective disease range, expected differences 
between specific conditions, and proportionally weighted cor-
rection factors. This approach could represent a viable alterna-
tive to analyte cutoff values in the process of raw data inter-
pretation, fostering their replacement with score-interpretation 
guidelines for a given condition.
mAteRiALs And metHOds
The Region 4 Stork MS/MS data project is a Web-based applica-
tion developed using Microsoft.NET framework 3.5 and SQL 
Server 2008.6 The criteria for case definition are set by the local 
protocols of the individual participating sites and by overarch-
ing requirements that have been described previously.6 As of 
15 December 2011, the MS/MS profiles of 12,077 patients 
affected with 60 metabolic disorders and of 644 heterozygote 
carriers for 12 conditions have been collected in this database. 
These profiles have served as the training set for the develop-
ment of the postanalytical tools, and their number continues 
to expand. Since the beginning of 2009, an average of 5.2 new 
cases has been added per day (2008: 1,796 cases; 2009: 1,734 
cases; 2010: 1,452 cases). The current population study trans-
lates to 767,408 discrete analyte concentrations and calculated 
intROdUctiOn
The Regional Genetics and Newborn Screening Collaboratives 
funded by the Maternal and Child Health Bureau have been 
very successful in improving the newborn screening infrastruc-
ture of the United States. One of these initiatives has supported 
a project to hasten the implementation of newborn screening by 
tandem mass spectrometry (MS/MS)1 and achieve uniformity 
of targets.2 The importance of this endeavor is underscored by 
the recent inclusion of expanded newborn screening among the 
10 great public health achievements of the past decade in the 
field of maternal and infant health.3
The specific objectives of the collaborative project are (i) 
to achieve consistency with the uniform panel adopted as 
the national standard by the Secretary of Health and Human 
Services4 and (ii) to improve analytical performance through 
the pursuit of the lowest achievable rates of false-positive and 
false-negative results.5 This project has grown to include 154 
public health programs and private laboratories worldwide, 
leading to the publication of 8,255 disease ranges and 114 cut-
off target ranges for amino acids, acylcarnitines, and related 
ratios.6,7
We have developed multivariate pattern-recognition software 
designed to convert metabolic profiles into a composite score 
driven by the degree of overlap between normal population and 
disease range. Clinical relevance of a marker is reached when 
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Purpose: To improve quality of newborn screening by tandem mass 
spectrometry with a novel approach made possible by the collabora-
tion of 154 laboratories in 49 countries.
methods: A database of 767,464 results from 12,721 cases affected 
with 60 conditions was used to build multivariate pattern recogni-
tion software that generates tools integrating multiple clinically sig-
nificant results into a single score. This score is determined by the 
overlap between normal and disease ranges, penetration within the 
disease range, differences between conditions, and weighted correc-
tion  factors.
Results: Ninety tools target either a single condition or the differ-
ential diagnosis between multiple conditions. Scores are expressed 
as the percentile rank among all cases with the same condition and 
are compared to interpretation guidelines. Retrospective evaluation 
of past cases suggests that these tools could have avoided at least half 
of 279 false-positive outcomes caused by carrier status for fatty-acid 
oxidation disorders and could have prevented 88% of known false-
negative events.
conclusions: Application of this computational approach to raw 
data is independent from single analyte cutoff values. In Minne-
sota, the tools have been a major contributing factor to the sustained 
achievement of a false-positive rate below 0.1% and a positive predic-
tive value above 60%.
Genet Med 2012:14(7):648–655
Key words: cutoff values; false-positive rate; inborn errors of 
metabolism; newborn screening; positive predictive value.
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ratios. Each case is assigned a unique code separate from any 
other traceable identifier, and no demographic information is 
collected except the calendar year of birth. Accordingly, this 
project has been reviewed and approved as a minimum-risk 
protocol by the Mayo Clinic Institutional Review Board (pro-
tocol PR09-001709-01).
The process and criteria used to create a tool are described 
in the Supplementary Material online. Tools can be generated 
for one or more conditions following a stepwise process that 
has four major components (Supplementary Table S1 online): 
(i) choice of scoring strategy and method to calculate correc-
tion factors; (ii) selection of markers; (iii) activation of differen-
tiators, outlier rules, and filters; and (iv) setup of interpretation 
guidelines. Different scoring strategies are available to elevate 
scores for conditions that have only a few informative markers 
(Supplementary Table S2 online). The correction factors, which 
can be either condition- or case-specific, are derived from the 
degree of overlap between the normal population and the dis-
ease range of each informative marker in a given condition. The 
degree of overlap is indeed the foundation of this novel method 
for interpreting quantitative results in a way that is unique to 
each condition and therefore not dependent on fixed analyte 
cutoff values. The selection of markers is based on an objec-
tive threshold of clinical significance, which is reached when 
the median of the disease range of a marker is above the 99 per-
centile of the normal population (high markers—i.e., abnormal 
when above the normal range) or below the 1 percentile (low 
markers).6 Differentiators, outlier rules, and filters are added to 
mitigate the potential impact of true negative cases (cases with 
completely normal results) to preserve the integrity of the tools 
and allow differential diagnosis between conditions.
As of 15 December 2011, a total of 90 active tools were acces-
sible on the website, 37 of which are applicable to the differential 
diagnosis of two or more conditions (Supplementary Figure S1 
online). Their intended use is to generate a score that drives the 
interpretation and resolution of cases with potentially abnormal 
MS/MS results. Case profiles can be entered individually (i.e., 
after the conventional flagging of abnormal results according to 
cutoff values, Supplementary Figure S2 online) or as batches 
containing many profiles (e.g., entire plates/daily runs) uploaded 
to the website using a health information exchange system.8
ResULts
This multivariate pattern-recognition software is applicable to a 
broad range of clinical applications. Expanded newborn screen-
ing is ideal for a clinical validation study because it involves 
many markers requiring pattern recognition and profile inter-
pretation. Their complexity is compounded by the rarity of 
most of the target conditions. At this stage, tools are based on 
data from neonatal blood spots and are not applicable to differ-
ent specimen types and to older patients.
Figure 1 shows a partial view of the tool (the data-entry win-
dow is not shown; see Supplementary Material online for an 
example of that panel) for argininosuccinic acid lyase deficiency,9 
a urea-cycle disorder that is included in the recommended 
uniform panel.2 The top part of the figure is a visual overlay of 
three elements for each informative analyte (red) and discrimina-
tor (gray)—the normal population range, the disease range, and 
the individual value—all shown after conversion to the multiple 
of the normal median on a log scale. The screening results of this 
particular case were not considered informative according to the 
cutoff value for citrulline applied by the testing laboratory at the 
time. The bottom part of the figure summarizes the calculated 
score as follows: (i) the absolute value of the calculated score; 
(ii) the percentile rank of the score in comparison to all available 
cases; (iii) the number of available cases with the condition under 
evaluation; and (iv) a visual display of all scores in comparison to 
interpretation guidelines. These are built as intervals where the 
score is considered as either being not informative or indicating 
that the condition is possible, likely, or very likely. Notably, in 
this false-negative case the score percentile rank was 29% (N = 
78) even with the omission from the tool of the unique marker 
of this condition, argininosuccinic acid. Following this event, 
the cutoff value of the program was reduced by 25% and this 
tool is being used on a regular basis. As of 15 December 2011, 
110 of the laboratories participating in the collaborative project 
have implemented a high cutoff value for citrulline and there-
fore are bound to encounter cases with hypercitrullinemia in 
disorders besides citrullinemia type I; the most common among 
these is indeed argininosuccinic acid lyase deficiency. Because 
63% of laboratories have a cutoff value above the recommended 
target range for citrulline (30–40 µmol/liter),6 they are likely to 
experience false-negative events like the one shown here. This 
is not a rare situation. The project database includes 86 cases 
(0.7% of the total count) that were reported as normal but in 
which a later diagnosis was based on clinical presentation. This 
set of cases is limited to those for which all the results required 
to calculate a score were available, but there are others, some 
extracted from the literature, with partial sets of data. Excluding 
conditions in which the poor sensitivity is driven by either a true 
lack of an informative marker (nonketotic hyperglycinemia) or 
the historical reliance on an ineffective marker (tyrosinemia 
type I),6 88% of the remaining cases (59 of 67 patients affected 
with 23 conditions) generated an informative score when evalu-
ated with the pertinent tool. Six of the eight false-negative cases 
with uninformative scores have been published.10–12 Overall, this 
anecdotal evidence suggests that, pending a prospective study 
of the impact of the interpretive tools, at least half of historical 
false-negative events could  perhaps have been avoided if these 
tools had been available and utilized.
Although sensitivity is of critical importance, the greatest 
opportunity for performance improvement in newborn screen-
ing, especially in a multiplex test environment, is found in the 
realm of specificity. The false-positive rate limited to testing by 
tandem mass spectrometry ranges between 5.99% and 0.03% 
(median: 0.46%) among the 68 sites that have shared their per-
formance metrics on the project website. A significant issue 
that drives high false-positive rates is the referral to follow-up 
of newborns with abnormal results due to heterozygosity (car-
rier status), a situation not uncommon for disorders such as 
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 medium-chain acyl-CoA dehydrogenase deficiency13 and very-
long-chain acyl-CoA dehydrogenase deficiency.14 In both con-
ditions, energy depletion due to prolonged labor and delivery 
may trigger the transient appearance of a biochemical pheno-
type mimicking affected status. Interpretive tools can facilitate 
the identification of carriers and consequently reduce the num-
ber of cases requiring follow-up. At the same time, use of these 
tools could prevent at least some of the false-negative events 
determined by cutoff values set inappropriately, as mentioned 
above, but they are not likely to recognize cases with completely 
uninformative biochemical phenotypes.10–12,15 Although several 
acylcarnitine species could be informative for the evaluation of 
these conditions,6 the most widely used markers are octanoyl-
carnitine (C8) and tetradecenoylcarnitine (C14:1), respectively. 
Figure 2a shows the distribution of paired C8 and C14:1 con-
centrations in four groups of cases: two with medium-chain 
acyl-CoA dehydrogenase deficiency (affected and carriers) and 
two with very-long-chain acyl-CoA dehydrogenase deficiency 
Figure 1 Partial display of the tool for argininosuccinic acid (AsA) lyase deficiency (two of the three panels; see supplementary material online 
for an example of the data-entry panel). This case was considered not informative on the basis of a cutoff for citrulline set inappropriately high. The top 
panel is an overlay graph of normal population, disease range, and the values entered to calculate a score. All values are expressed as µmol/l and converted 
to multiples of the normal median on a log scale. The bottom panel shows the calculated score, the percentile rank comparison to all available scores and the 
case count along with a graphic display of all available scores for the chosen condition, and a summary of interpretation guidelines.
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(affected and carriers). The figure also shows the median val-
ues of the two carrier ranges; both values are clearly above the 
median of all active cutoff values in the collaborative project. 
These data illustrate how common it may be to encounter an 
abnormal result due to heterozygosity, a dilemma that cannot 
be ignored by increasing the cutoff above the carrier range.16
Figure 2 scatter plots of acylcarnitine results and of condition scores. (a) Scatter plot of C8 and C14:1 in four conditions: medium-chain acyl-CoA 
dehydrogenase (MCAD) deficiency, heterozygote carriers of MCAD deficiency, very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, and heterozygote 
carriers of VLCAD deficiency. The number of cases included in the figure are shown in the insert in the upper right corner, which shows a wider range of values 
in affected patients (highest values for C8 and C14:1 are 61.8 µmol/l and 13.1 µmol/l, respectively). The horizontal and vertical red dotted lines correspond to the 
median cutoff value among all laboratories (C8 0.35 µmol/l, N = 119; C14:1 0.60 µmol/l, N = 113). The horizontal and vertical black dotted lines correspond to 
the median of the ranges in the two carrier groups (C8 0.44 µmol/l, N = 147; C14:1 0.84 µmol/l, N = 123). (b) Dual scatter plot comparing the scores of MCAD 
deficiency (dark circles) and MCAD-deficiency heterozygote carriers (light circles). The dotted lines shown as x-axis and y-axis thresholds define the quadrants of 
the plot where a combined score (x-axis: <27%, y-axis: >96%; x-axis: >27%, y-axis: <96%) is consistent with carrier status and affected status, respectively. The 
upper right quadrant defines the small area where a combined score is not informative to discriminate carrier vs. affected (hence to be resolved by biochemical 
and molecular testing); the lower left quadrant is consistent with normal status. (c) Dual scatter plot comparing the scores of VLCAD deficiency (dark circles) and 
VLCAD-deficiency heterozygote carriers (light circles). The dotted lines shown as x-axis and y-axis thresholds define the quadrants of the plot where a combined 
score (x-axis: <25%, y-axis: >85%; x-axis: >25%, y-axis: <85%) is consistent with carrier status and affected status, respectively. Symbols are the same as in 
panel b. The upper right quadrant defines the area where a combined score is not informative to discriminate carrier vs. affected (to be resolved by biochemical 
and molecular testing); the lower left quadrant is consistent with normal status.
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The clinical utility of the two conditions tools and, when paired 
appropriately, of the dual scatter plot is illustrated in  panels 
b and c of Figure 2. They show the scores of two cases, each 
generated by a tool based on the same markers but designed to 
recognize the differences between a target condition (affected) 
and a secondary condition (carrier). A red diamond symbol 
marks the location of the combined scores of a medium-chain 
acyl-CoA dehydrogenase deficiency carrier with a concentra-
tion of C8 exactly at the median of the carrier range, Figure 2c 
does the same for a very long-chain acyl-CoA dehydrogenase 
deficiency carrier. Cases with values below the median gener-
ate scores that are even more segregated, suggesting that, as in 
the opposite scenario of false-negative events described previ-
ously, in at least half of these cases referred to follow-up the cost 
of unnecessary tests and a variety of unfavorable outcomes17 
could have been prevented. Furthermore, the application of 
the same postanalytical process to acylcarnitine profiles gener-
ated in vitro under controlled circumstances with the fatty-acid 
probe assay18 results in a complete separation between the two 
groups (data not shown). A systematic use of this tool to inte-
grate biochemical and enzymatic results in cases with incon-
clusive genotyping results has the potential to resolve existing 
differences of opinion regarding the proper way to follow up 
an abnormal newborn screening result.19,20 The in vitro work is 
beyond the scope of this report and will be published separately 
(E.H. Smith, D. Matern, et al., unpublished data).
The impact of this objective, evidence-driven approach to the 
interpretation of laboratory results could be substantial. As an 
example, Figure 3 shows a longitudinal summary of the per-
formance metrics of newborn screening by tandem mass spec-
trometry in Minnesota over the period 2002–2010. Minnesota 
has been the first adopter of all quality-improvement tools made 
available to the participants of the collaborative project since 2005. 
The first panel shows the number of true-positive cases per year 
normalized per 100,000 births. Cases of Hmong ethnicity with 
2-methylbutyryl-CoA dehydrogenase deficiency21 (2–19 new 
cases per year) were not included in this metric to eliminate the 
bias of a common disorder in an overrepresented minority. The 
other two panels show a trend over time of sustained improve-
ment of two performance metrics as described previously,5 both 
greatly exceeding the proposed targets of adequate performance 
(false-positive rate: 0.30%; positive predictive value: 20%).
discUssiOn
The primary objective of the Region 4 collaborative project 
is to promote improvement of laboratory quality of newborn 
Figure 3 Performance metrics of expanded newborn screening by tandem mass spectrometry in minnesota, 2002–2010. The birth volume is 
between 68,000 and 74,000 per year. As result of an ongoing public–private partnership, testing by tandem mass spectrometry was transferred from the 
Minnesota Department of Health to the Mayo Clinic College of Medicine in June 2004. (a) Number of true-positive cases per year normalized to 100,000 
births. The dotted line indicates the average (55.8/year/100,000 births). (b) Trend of false-positive rate. This metric is expressed as the proportion of positive 
tests in subjects proven by follow-up evaluation not to have one of the conditions targeted by the Minnesota program.7 (c) Trend of positive predictive value. 
This metric is expressed as the probability that a newborn is affected with a condition when restricted to cases with a positive test.7 Between June 2004 and 
December 2010, no false-negative events were brought to the attention of the program with respect to a condition included in the uniform panel.3
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screening by tandem mass spectrometry. Dealing with rare 
conditions of undetermined prevalence, a database of mean-
ingful clinical utility could be produced only through an 
unprecedented level of cooperation and collaboration on a 
global scale. The database has led to a new and original type 
of interpretive tool to achieve reduction in both false-negative 
events and false-positive outcomes. More traditional statistical 
methods for separation of cases from noncases, such as likeli-
hood ratio methods and discriminant analysis,22 are not appro-
priate in the current situation because they assume a multivari-
ate normal distribution of the analyte values in the cases that is 
not observed. Although many of the detected disorders arise 
from mutations in a single gene, the variability of the mutations 
and the extent of the corresponding phenotypic variation are 
unknown. As such, most of the disease populations are com-
plex mixtures that cannot be modeled with simple parametric 
distributions. Reliable information for some of the required 
characteristics, for example, the prevalence of the disease and 
the complexity of the differential diagnosis needed for a major-
ity of the informative markers, is also lacking. A further disal-
lowing complexity is the number of covariance parameters to 
be estimated, which vastly exceeds the number of cases of all 
but the most common of the disorders, making the parametric 
distribution subject to significant bias.
The lack of traditional analyte cutoff values may seem coun-
terintuitive for reporting quantitative laboratory test results on 
which binary decisions will be based. However, the basic tenet 
of this multivariate pattern-recognition software is that an 
abnormal result is not defined exclusively by a deviation from 
a statistical definition of normal. The software also evaluates 
how consistent a result is with the analyte disease range estab-
lished separately for each condition, an assessment that is novel 
and more informative than a traditional “one size fits all” cutoff 
value, and is made possible by a database of true-positive cases 
of unprecedented size. Another distinctive advantage of the 
postanalytical tools is the opportunity to calibrate any decision 
with an element that has not been taken full advantage of so far, 
which is the degree of overlap between normal population and 
disease range.
The interpretive tools first became available in January 2009. 
A conservative estimate of the utilization of the versions based 
on static spreadsheets is on the order of tens of thousands of 
downloads; more than 17,000 page views have been recorded 
since the initial release of the online tools (23 March 2011). The 
feedback from a diverse spectrum of users, laboratorians, and 
clinicians has been consistently positive, with indications that 
these tools are now used in clinical practice on a regular basis 
and indeed are effective, providing independent verification of 
the single-site evidence shown in Figure 3. A sustained trend of 
constant improvement is significant because cost–benefit anal-
ysis, expense management, and optimization of resource utili-
zation are high priorities in these times of increasing financial 
constraints, and the public health infrastructure is not exempt 
from the demand for reducing the cost of health-care services. 
Future recommendations to expand the uniform newborn 
screening panel with the addition of more conditions23–25 will 
raise this pressure even more.
This approach is flexible by design and certainly not limited to 
amino acids and acylcarnitines. It has already been successfully 
applied to other multianalyte profiles currently used as either 
primary or second-tier newborn screening tests, for example, 
for the interpretation of steroid profiles in congenital adrenal 
hyperplasia26 and of C20-C26 lysophosphatidylcholine species in 
X-linked adrenoleukodystrophy and other peroxisomal disor-
ders.27 The availability of more diverse applications is limited 
only by the gathering of sufficient data of the normal popula-
tion and of patients affected with the target condition(s).
The software continues to incorporate improvements sug-
gested by users, for example, the ability to customize the pool of 
percentiles and affected cases relied on to calculate scores. Users 
have the option to display scores based on subgroups of cases, 
either their own cases, those belonging to a specific country 
or, in the future, contributed by laboratories having the closest 
participant profile in terms of analyte percentiles in the normal 
population. Additional functions scheduled to be released in the 
near future are an “all conditions” tool (an unrestricted evalua-
tion of full amino acid and acylcarnitine profiles to suggest any 
possible diagnosis) and interfaces to download entire batches of 
raw data from existing commercial software. Additional appli-
cations unrelated to newborn screening will become routinely 
available to span a broad spectrum of either clinical or research 
endeavors. This evidence-based approach could add substantial 
value to patient care by providing a comprehensive interpreta-
tion of complex laboratory profiles driven by cumulative/mul-
tisite evidence and by objective peer comparison.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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